INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Baxter International, Inc. of Class Action Lawsuit And Upcoming Deadlines – BAX

NEW YORK CITY, NY / ACCESS Newswire / October 23, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Baxter International, Inc. ("Baxter" or the "Company") (NYSE:BAX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are […]

Howard Community College Earns National FamilyU Seal for Exemplary Support of Student Parents

Howard Community College Earns National FamilyU Seal for Exemplary Support of Student Parents GlobeNewswire October 23, 2025 COLUMBIA, MD, Oct. 23, 2025 (GLOBE NEWSWIRE) — Howard Community College has been awarded the prestigious FamilyU Seal, a national certification recognizing higher education institutions that are actively investing in student-parent success. Presented by Generation Hope, the Family

New Origins Expands Outpatient Capacity for Men Across the Inland Empire, Serving San Bernardino and Riverside Counties

Redlands, CA – New Origins announced an expansion of its men’s outpatient addiction treatment capacity to better serve the Inland Empire. The enhancement increases access for adults in San Bernardino and Riverside Counties who need structured, evidence-based care while maintaining work, school, family, and community commitments. The Redlands location at 101 E Redlands Blvd #200

InventHelp Inventor Develops New Adult Diaper (NJR-311)

“I wanted to create a new adult diaper to protect incontinent individuals against wetness and discomfort during the day and night,” said an inventor, from Edison, N.J., “so I invented the S U C D. My design would channel urine out of the diaper to help keep the user dry and comfortable.” https://mma.prnewswire.com/media/2099578/InventHelp_Logo_jpg_Logo.jpg The patent-pending

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MediaAlpha, Inc. – MAX

Pomerantz LLP is investigating claims on behalf of investors of MediaAlpha, Inc. (“MediaAlpha” or the “Company”) (NYSE: MAX).Such investors are advised to contact Danielle Peyton at newaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for

MaidCentral Strategy Summit Celebrated as Transformative Event for the Residential Cleaning Industry

The MaidCentral Strategy Summit 2025, held September 17-19 at Castle Keepers House Cleaning in North Charleston, united residential cleaning business leaders for three days of masterclasses, keynote sessions, and data-driven success stories. Attendees hailed the Summit as the most impactful event in the residential cleaning industry, setting a new benchmark for professional development, innovation, and

FFIV Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors with Significant Losses to Contact the Firm

FFIV Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages F5, Inc. (NASDAQ: FFIV) Investors with Significant Losses to Contact the Firm GlobeNewswire October 23, 2025 RADNOR, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws

ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

(NASDAQ:ALXO), -Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC class and continued evaluation in first-in-human trial –Initial safety data from ongoing ALX2004 Phase 1 trial anticipated in the first half of

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

(NASDAQ:ZYME), Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer 64% overall response rate in gynecological cancers at doses greater-than or equal to6.4mg/kg Responses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic

Sports.com Builds on 10 Million-View Milestone with Second Season of Hit LATAM Series Maximo Futbol

Sports.com Builds on 10 Million-View Milestone with Second Season of Hit LATAM Series Maximo Futbol SEGG Media Expands Original-Content Footprint as Sports.com Studios Greenlights Season Two GlobeNewswire October 23, 2025 FORT WORTH, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) — SEGG Media Corporation (NASDAQ: SEGG, LTRYW) (“SEGG Media” or the “Company”), the global sports, entertainment, and

Scroll to Top